Display options
Cite
Sun R, Koubaa I, Limkin EJ, et al. Locally advanced cervical cancer with bladder invasion: clinical outcomes and predictive factors for vesicovaginal fistulae. Oncotarget. 2018;9(10):9299-9310doi: 10.18632/oncotarget.24271.
Sun, R., Koubaa, I., Limkin, E. J., Dumas, I., Bentivegna, E., Castanon, E., Gouy, S., Baratiny, C., Monnot, F., Maroun, P., Ammari, S., Zareski, E., Balleyguier, C., Deutsch, �. �., Morice, P., Haie-Meder, C., & Chargari, C. (2018). Locally advanced cervical cancer with bladder invasion: clinical outcomes and predictive factors for vesicovaginal fistulae. Oncotarget, 9(10), 9299-9310. https://doi.org/10.18632/oncotarget.24271
Sun, Roger, et al. "Locally advanced cervical cancer with bladder invasion: clinical outcomes and predictive factors for vesicovaginal fistulae." Oncotarget vol. 9,10 (2018): 9299-9310. doi: https://doi.org/10.18632/oncotarget.24271
Sun R, Koubaa I, Limkin EJ, Dumas I, Bentivegna E, Castanon E, Gouy S, Baratiny C, Monnot F, Maroun P, Ammari S, Zareski E, Balleyguier C, Deutsch É, Morice P, Haie-Meder C, Chargari C. Locally advanced cervical cancer with bladder invasion: clinical outcomes and predictive factors for vesicovaginal fistulae. Oncotarget. 2018 Jan 18;9(10):9299-9310. doi: 10.18632/oncotarget.24271. eCollection 2018 Feb 06. PMID: 29507691; PMCID: PMC5823628.
Copy Download .nbib Format: NLM
Share it on

Oncotarget. 2018 Jan 18;9(10):9299-9310. doi: 10.18632/oncotarget.24271. eCollection 2018 Feb 06.

Locally advanced cervical cancer with bladder invasion: clinical outcomes and predictive factors for vesicovaginal fistulae.

Oncotarget

Roger Sun, Ines Koubaa, Elaine Johanna Limkin, Isabelle Dumas, Enrica Bentivegna, Eduardo Castanon, Sébastien Gouy, Cynthia Baratiny, Fyo Monnot, Pierre Maroun, Samy Ammari, Elise Zareski, Corinne Balleyguier, Éric Deutsch, Philippe Morice, Christine Haie-Meder, Cyrus Chargari

Affiliations

  1. Department of Radiotherapy, Gustave Roussy Cancer Campus, Villejuif, France.
  2. INSERM U1030 Molecular Radiotherapy, Gustave Roussy Cancer Campus, Villejuif, France.
  3. Department of Radiology, Gustave Roussy Cancer Campus, Villejuif, France.
  4. Department of Medical Physics, Gustave Roussy Cancer Campus, Villejuif, France.
  5. Department of Surgery, Gustave Roussy Cancer Campus, Villejuif, France.
  6. Department of Drug development, Gustave Roussy Cancer Campus, Villejuif, France.
  7. Université Paris Sud, Université Paris-Saclay, Le Kremlin-Bicêtre, France.
  8. Institut de Recherche Biomédicale des Armées, Brétigny-sur-Orge, France.
  9. French Military Health Service Academy, Ecole du Val-de-Grace, Paris, France.

PMID: 29507691 PMCID: PMC5823628 DOI: 10.18632/oncotarget.24271

Abstract

OBJECTIVE: We report outcomes of cervical cancer patients with bladder invasion (CCBI) at diagnosis, with focus on the incidence and predictive factors of vesicovaginal fistula (VVF).

RESULTS: Seventy-one patients were identified. Twenty-one (30%) had para-aortic nodal involvement. Eight had VVF at diagnosis. With a mean follow-up time of 34.2 months (range: 1.9 months-14.8 years), among 63 patients without VVF at diagnosis, 15 (24%) developed VVF. A VVF occurred in 19% of patients without local relapses (9/48) and 40% of patients with local relapse (6/15). Two-year overall survival (OS), disease-free survival (DFS) and local control rates were 56.4% (95% CI: 44.1-67.9%), 39.1% (95% CI: 28.1-51.4%) and 63.8% (95% CI: 50.4-75.4%), respectively. Para-aortic nodes were associated with poorer OS (adjusted HR = 3.78,

CONCLUSIONS: A curative intent strategy including brachytherapy is feasible in patients with CCBI, with VVF occurrence in 24% of the patients. MRI patterns help predicting VVF occurrence.

METHODS: Patients with locally advanced CCBI treated with (chemo)radiation ± brachytherapy in our institute from 1989 to 2015 were analyzed. Reviews of baseline magnetic resonance imaging (MRI) scans were carried out blind to clinical data, retrieving potential parameters correlated to VVF formation (including necrosis and tumor volume).

Keywords: bladder invasion; brachytherapy; cervical cancer; locally advanced; vesicovaginal fistula

Conflict of interest statement

CONFLICTS OF INTEREST None.

References

  1. Gynecol Oncol. 2008 Jun;109(3):429; author repply 429-30 - PubMed
  2. Cancer Radiother. 2016 Oct;20(6-7):622-8 - PubMed
  3. Gynecol Oncol. 2011 Jun 1;121(3):542-5 - PubMed
  4. Ann Oncol. 2017 Jul 1;28(suppl_4):iv72-iv83 - PubMed
  5. Int J Radiat Oncol Biol Phys. 2014 Mar 1;88(3):537-9 - PubMed
  6. Radiother Oncol. 2016 Sep;120(3):365-369 - PubMed
  7. Cancer. 2011 May 1;117(9):1928-34 - PubMed
  8. Lancet Oncol. 2012 May;13(5):e212-20 - PubMed
  9. Radiother Oncol. 2007 May;83(2):148-55 - PubMed
  10. Int J Radiat Oncol Biol Phys. 2009 May 1;74(1):133-9 - PubMed
  11. J Radiat Res. 2016 Nov;57(6):684-690 - PubMed
  12. Int J Gynecol Cancer. 2010 Apr;20(3):471-5 - PubMed
  13. Radiother Oncol. 2012 Apr;103(1):113-22 - PubMed
  14. Int J Gynaecol Obstet. 2015 Oct;131 Suppl 2:S88-95 - PubMed
  15. Anticancer Res. 2013 Nov;33(11):4989-94 - PubMed
  16. Gynecol Oncol. 1989 Mar;32(3):323-6 - PubMed
  17. Oncologist. 2013;18(4):415-22 - PubMed
  18. Radiother Oncol. 2006 Jan;78(1):67-77 - PubMed
  19. Radiother Oncol. 2010 Aug;96(2):161-5 - PubMed
  20. Int J Radiat Oncol Biol Phys. 2004 Nov 15;60(4):1144-53 - PubMed
  21. Int J Radiat Oncol Biol Phys. 2013 Sep 1;87(1):111-9 - PubMed
  22. Gynecol Oncol. 2007 Sep;106(3):498-501 - PubMed
  23. Lancet. 2001 Sep 8;358(9284):781-6 - PubMed
  24. Radiother Oncol. 2005 Mar;74(3):235-45 - PubMed
  25. Am J Obstet Gynecol. 1972 May 15;113(2):239-46 - PubMed
  26. Clin Oncol (R Coll Radiol). 2016 Mar;28(3):171-7 - PubMed
  27. Cancer. 2006 Feb 15;106(4):914-22 - PubMed
  28. Cochrane Database Syst Rev. 2010 Jan 20;(1):CD008285 - PubMed
  29. Radiat Med. 1990 Sep-Oct;8(5):184-7 - PubMed
  30. Br J Radiol. 1985 Jun;58(690):515-28 - PubMed

Publication Types